Literature DB >> 34977193

Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel.

Wael Al Mahmeed1, Khalid Al-Rasadi2, Yajnavalka Banerjee3, Antonio Ceriello4, Francesco Cosentino5, Massimo Galia6, Su-Yen Goh7, Peter Kempler8, Nader Lessan9, Nikolaos Papanas10, Ali A Rizvi11,12, Raul D Santos13,14, Anca P Stoian15, Peter P Toth16, Manfredi Rizzo12,15,17.   

Abstract

Efforts in the fight against COVID-19 are achieving success in many parts of the world, although progress remains slow in other regions. We believe that a syndemic approach needs to be adopted to address this pandemic given the strong apparent interplay between COVID-19, its related complications, and the socio-structural environment. We have assembled an international, multidisciplinary group of researchers and clinical practitioners to promote a novel syndemic approach to COVID-19: the CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO). This geographically diverse group aims to facilitate collaborative-networking and scientific exchanges between researchers and clinicians facing a multitude of challenges on different continents during the pandemic. In the present article we present our "manifesto", with the intent to provide evidence-based guidance to the global medical and scientific community for better management of patients both during and after the current pandemic.
Copyright © 2021 Al Mahmeed, Al-Rasadi, Banerjee, Ceriello, Cosentino, Galia, Goh, Kempler, Lessan, Papanas, Rizvi, Santos, Stoian, Toth, Rizzo and The CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO).

Entities:  

Keywords:  COVID-19; cardiovascular diseases; complications; diabetes; pandemic; syndemic

Year:  2021        PMID: 34977193      PMCID: PMC8715947          DOI: 10.3389/fcvm.2021.787761

Source DB:  PubMed          Journal:  Front Cardiovasc Med        ISSN: 2297-055X


Introduction

There is a bidirectional pathophysiologic relationship between coronavirus disease 2019 (COVID-19) and cardiometabolic diseases, and individuals at risk of the latter require careful consideration as the global pandemic continues to take its toll. Diabetes, obesity, and cardiovascular disease are associated with an increased risk for severe forms of COVID-19 and resulting death (1–6). At the same time, patients with COVID-19 infection are more prone to the development of new-onset diabetes mellitus (7). Investigators from different areas have emphasized the clinical relevance of the increased incidence of diabetes after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (8, 9). Furthermore, COVID-19 is associated with cardiovascular injury attributed to heightened inflammation, endothelial dysfunction and microthrombi formation (10–13). Endothelial dysfunction plays an important role in the pathogenesis of COVID-19, particularly in patients with pre-existing hypertension, diabetes, obesity and cardiovascular diseases (14). The endothelium, and particularly pulmonary endothelium, seems to be a key target organ in COVID-19 patients and its dysfunction has been shown to cause an impaired organ perfusion that can generate acute myocardial injury, renal failure, and a procoagulant state resulting in thromboembolic events (14–16). It has been shown that SARS-CoV-2 can induce several pro-inflammatory cytokines (17) and that patients with severe COVID-19 develop a “cytokine storm syndrome” (18). Since these first observations it is become clear that the same cytokines that induce aberrant endothelial function may also trigger the acute phase response, which, in combination with local endothelial dysfunction, can lead to clinical consequences (14); indeed, inflammatory cytokines have a major role in both diabetes and cardiovascular diseases (19). Other authors have shown that COVID-19 is associated with myocardial damage such as myocarditis, arrhythmia and reduced left ventricular ejection fraction (20), all of which are associated to increased mortality risk (21). Plasma cardiac biomarkers, such as high sensitivity troponin, creatine kinase and N-terminal pro-B-type natriuretic peptide, are also associated with COVID-19 severity in adults and children (22, 23). Beyond the direct effect of COVID-19 on the cardiovascular system and metabolic homeostasis, subjects with pre-existing cardiometabolic issues appear to be at a significantly higher risk of complications owing to reduced physical activity, altered eating behaviors, and lack of access to healthcare (24). This encapsulates the so-called “indirect” impact of COVID-19 and indeed a higher incidence of cardiovascular complications and fatalities has been documented secondary to the pandemic, for example in Italy (25). Even in New York City, emergency calls for cardiac arrests rose exponentially in the weeks when COVID-19 infections approached their zenith (26). Beyond deaths attributed directly to COVID-19, a large contribution to the excess mortality reported (27) is attributable to the indirect factors, including the disruption of the proper management of many clinical conditions–including cardiometabolic diseases–by the rapid conversion of entire hospitals or clinical units to deliver COVID-19-specific care (28). This situation has been exacerbated in some geographical areas by increased unemployment, economic collapse, and widespread poverty (29). Indeed, increasing socio-economic disparities have come to the forefront in many populations during the pandemic, rendering people more vulnerable to economic, nutritional, social, and medical insecurity, particularly during prolonged periods of necessary government-imposed restrictions or lockdowns (30). In addition, the spread of the virus and the related complications and fatalities have been facilitated among subjects with the poorest socio-economic conditions and those living in overcrowded areas (29–31). Socio-economic inequalities are of increasing relevance during the ongoing vaccination campaigns as they contribute to disparities in care across different ethnic populations and geographical areas (32).

Importance of a Syndemic Approach

The enormous efforts by many different organizations and individuals involved in the fight against COVID-19 have had some success in many parts of the world. However, this has not been universal and progress has been slow in many other regions. We believe that a syndemic approach needs to be adopted for addressing this pandemic (33) given the strong apparent interplay between COVID-19, its related complications, and the socio-structural environment. The term syndemic (from ancient Greek: syn, together; demos, people) emphasizes the relevance of biological, social, economic, and environmental factors in the health of individuals and populations (29). Physicians have an obligation to understand their patients' social, economic, and environmental situations and to utilize the tools available in existing health systems to improve their access to care. It is also expected that many health systems will continue to be under significant economic pressure, which may contribute to a reduced quality of care for patients with chronic conditions. Another challenge is represented by the so-called long-COVID syndrome, which is a clinical condition present in subjects who have either recovered from COVID-19 but still report lasting effects of the infection or have had the usual symptoms for far longer than would be expected (34). Of increasing current interest are the neurological and neuropsychiatric complications (35), since several studies have reported a broad spectrum of symptoms, from the milder manifestations of memory loss, sleep disorders and impaired concentration to more serious cognitive decline, major depression or persistent delirium (36). Thus, there is an urgent need to better understand the long-term effects of COVID-19 on brain function, behavior and cognition. As a component of a holistic approach to the management of patients with COVID-19, mental health assessment should be included.

Capisco: An International, Multidisciplinary Collaboration

We believe it is crucial to improve interactions between specialists working in different disciplines, since insufficient cooperation has contributed to the indirect impact of COVID-19 (37). Furthermore, the pandemic has adversely medical education in many ways, for example owing to shifts to distance-learning modalities and decline in clinical clerkship due to the cancelation of routine patient appointments and surgical procedures and a transition to greater use of telemedicine (38). In response to these challenges we have recently assembled the Cardiometabolic Panel of International Experts on Syndemic COVID-19 (CAPISCO), a group of international researchers and clinical practitioners from many different disciplines including (but not limited to) diabetology, endocrinology, cardiology, lipidology, internal medicine, radiology, preventive medicine, public health and biochemistry–providing a multi-disciplinary representation in a novel approach to COVID-19 (Figure 1). We also emphasized geographical diversity when convening the group in order to facilitate collaborative-networking and scientific exchanges between researchers and clinicians facing a multitude of challenges in different continents during the pandemic.
Figure 1

A novel multi-disciplinary syndemic approach to cardiometabolic diseases during COVID-19.

A novel multi-disciplinary syndemic approach to cardiometabolic diseases during COVID-19. Members of CAPISCO intend to collaboratively investigate: how patients with cardiometabolic diseases and its complications are currently being managed and treated and the extent to which the pandemic impacts proper management, with a view to identifying, categorizing and defining innovative strategies to overcome potential barriers and disparities; why differences in COVID-19 mortality rates have been reported among various countries, beyond the prevalence of the disease per se, with the aim to elucidate the social, economic and environmental factors potentially impacting clinical outcomes; whether telemedicine is a reliable and useful tool to deliver high-quality patient care in light of experience gained during the pandemic; across different geographical areas we aim to investigate: what was successfully implemented and how, what was not successfully implemented and why, and what still needs to be improved; how to assess the burden and late consequences of delayed management of cardiometabolic disease and other conditions due to COVID-19. Ultimately, the overarching aim of CAPISCO is to give evidence-based guidance for the management of patients with cardiometabolic diseases during and after COVID-19 based on a syndemic approach. In terms of methodology, we plan to use a systematic approach, including systematic literature searches, formal quality-grading and analysis of collected studies, resulting in graded levels of recommendations. We also intend to make a roadmap plan of further research avenues once the data from the above indicated tools becomes available; this may also involve cooperation with health authorities and other international organizations.

Conclusions

In conclusion, we believe it is crucial to view COVID-19 through a syndemic lens to properly tackle the interlinked public health, medical, social and economic challenges that amplify each other in this crisis. The acronym of our expert panel, CAPISCO, is meaningful, since the word “capisco” means in Italian, “I understand”. CAPISCO contributions will promote a holistic approach for all patients with cardiometabolic diseases based on solid, validated scientific research and clinical expertise. We hope that physicians around the world will be able to use them to help benefit clinical care, follow-up, and monitoring of their patients during and after the COVID-19 pandemic.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Author Contributions

This article is the result of three expert panel meetings conducted virtually between May and July 2021. MR and WA, co-chairs of CAPISCO, prepared the first draft of this article, which was first critically discussed and reviewed with AR, AC, and AS, and then extensively reviewed by all the other members. All authors have equally contributed to the final manuscript and are listed alphabetically.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
  36 in total

1.  Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era.

Authors:  Antonio Ceriello; Eberhard Standl; Doina Catrinoiu; Baruch Itzhak; Nebojsa M Lalic; Dario Rahelic; Oliver Schnell; Jan Škrha; Paul Valensi
Journal:  Diabetes Care       Date:  2020-05-14       Impact factor: 19.112

2.  Comparison of Reported Deaths From COVID-19 and Increase in Total Mortality in Italy.

Authors:  Manfredi Rizzo; Luca Foresti; Nicola Montano
Journal:  JAMA Intern Med       Date:  2020-09-01       Impact factor: 21.873

Review 3.  Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.

Authors:  Zhengchuan Zhu; Miaoran Wang; Wei Lin; Qiaoyan Cai; Ling Zhang; Daxin Chen; Fei Liu; Xiaoman Xiong; Jianfeng Chu; Jun Peng; Keji Chen
Journal:  Immun Inflamm Dis       Date:  2021-08-18

4.  Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.

Authors:  S Kritas; P Conti; G Ronconi; A Caraffa; C Gallenga; R Ross; I Frydas
Journal:  J Biol Regul Homeost Agents       Date:  2020 March-April,       Impact factor: 1.711

5.  Lessons from COVID-19: How human behaviour may influence the science.

Authors:  Antonio Ceriello
Journal:  Diabetes Res Clin Pract       Date:  2020-10-02       Impact factor: 5.602

6.  The COVID-19 Pan-Syndemic - will we ever learn?

Authors:  Srivatsan Padmanabhan
Journal:  Clin Infect Dis       Date:  2020-11-29       Impact factor: 9.079

Review 7.  Post-Acute COVID-19 Neurological Syndrome: A New Medical Challenge.

Authors:  Domenico Nuzzo; Sonya Vasto; Luca Scalisi; Salvatore Cottone; Gaetano Cambula; Manfredi Rizzo; Daniela Giacomazza; Pasquale Picone
Journal:  J Clin Med       Date:  2021-05-01       Impact factor: 4.241

8.  Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology.

Authors:  Amit Khera; Seth J Baum; Ty J Gluckman; Martha Gulati; Seth S Martin; Erin D Michos; Ann Marie Navar; Pam R Taub; Peter P Toth; Salim S Virani; Nathan D Wong; Michael D Shapiro
Journal:  Am J Prev Cardiol       Date:  2020-05-01

9.  Clinical conditions and echocardiographic parameters associated with mortality in COVID-19.

Authors:  Angelo Silverio; Marco Di Maio; Fernando Scudiero; Vincenzo Russo; Luca Esposito; Emilio Attena; Salvatore Pezzullo; Guido Parodi; Antonello D'Andrea; Antonio Damato; Antonio Silvestro; Patrizia Iannece; Michele Bellino; Davide Di Vece; Anna Borrelli; Rodolfo Citro; Carmine Vecchione; Gennaro Galasso
Journal:  Eur J Clin Invest       Date:  2021-07-20       Impact factor: 5.722

View more
  12 in total

Review 1.  Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Arrigo F G Cicero; Andrej Janez; Anca Pantea Stoian; Alper Sonmez; Manfredi Rizzo
Journal:  Medicina (Kaunas)       Date:  2022-02-16       Impact factor: 2.430

2.  Commentary: A Machine-Generated View of the Role of Blood Glucose Levels in the Severity of COVID-19. A Metabolic Endocrinology Perspective.

Authors:  Jeff M P Holly
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-28       Impact factor: 6.055

3.  The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.

Authors:  Samuel J P Malkin; Davide Carvalho; Catarina Costa; Vasco Conde; Barnaby Hunt
Journal:  Diabetol Metab Syndr       Date:  2022-02-14       Impact factor: 3.320

Review 4.  A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Khalid Al Rasadi; Mustafa Cesur; José Silva-Nunes; Anca Pantea Stoian; Manfredi Rizzo
Journal:  Metabolites       Date:  2022-01-24

5.  Cholesterol Metabolic Markers for Differential Evaluation of Patients with Hyperlipidemia and Familial Hypercholesterolemia.

Authors:  Zhi-Zhao Li; Qiong Huang; Xiao-Li Yang; Jieqiong Zeng; Qi-Hui Wang; Hai-Ming Tang; Zhen-Qiu Yu; Yu-Qing Song; Yang Liu
Journal:  Dis Markers       Date:  2022-04-21       Impact factor: 3.464

Review 6.  Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes.

Authors:  Angelo Maria Patti; Rosaria Vincenza Giglio; Nikolaos Papanas; Dragos Serban; Anca Pantea Stoian; Kalliopi Pafili; Khalid Al Rasadi; Kanya Rajagopalan; Ali A Rizvi; Marcello Ciaccio; Manfredi Rizzo
Journal:  Medicina (Kaunas)       Date:  2022-01-11       Impact factor: 2.430

Review 7.  Consequences of COVID-19 for the Pancreas.

Authors:  Urszula Abramczyk; Maciej Nowaczyński; Adam Słomczyński; Piotr Wojnicz; Piotr Zatyka; Aleksandra Kuzan
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

8.  Correlations between Diabetes Mellitus Self-Care Activities and Glycaemic Control in the Adult Population: A Cross-Sectional Study.

Authors:  Mihaela Simona Popoviciu; Violeta Nicoleta Marin; Cosmin Mihai Vesa; Simona Diana Stefan; Roxana Adriana Stoica; Cristian Serafinceanu; Emanuele Maria Merlo; Ali A Rizvi; Manfredi Rizzo; Stefan Busnatu; Anca Pantea Stoian
Journal:  Healthcare (Basel)       Date:  2022-01-17

9.  The Role of Fructose as a Cardiovascular Risk Factor: An Update.

Authors:  Stefan-Sebastian Busnatu; Teodor Salmen; Maria-Alexandra Pana; Manfredi Rizzo; Tiziana Stallone; Nikolaos Papanas; Djordje Popovic; Denisa Tanasescu; Dragos Serban; Anca Pantea Stoian
Journal:  Metabolites       Date:  2022-01-12

Review 10.  Metformin: Sex/Gender Differences in Its Uses and Effects-Narrative Review.

Authors:  Ioannis Ilias; Manfredi Rizzo; Lina Zabuliene
Journal:  Medicina (Kaunas)       Date:  2022-03-16       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.